Barclays
GPCR icon

Barclays’s Structure Therapeutics GPCR Stock Holding History

Barclays’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$925K Buy
19,188
+11,355
+145% +$777K ﹤0.01% 2807
2025
Q4 		$545K Buy
7,833
+4,060
+108% +$166K ﹤0.01% 3794
2025
Q3 		$106K Sell
3,773
-2,555
-40% -$50.9K ﹤0.01% 4595
2025
Q2 		$131K Buy
6,328
+1,016
+19% +$22.3K ﹤0.01% 4500
2025
Q1 		$92K Sell
5,312
-110,359
-95% -$2.7M ﹤0.01% 4438
2024
Q4 		$3.14M Buy
115,671
+34,533
+43% +$1.23M ﹤0.01% 2551
2024
Q3 		$3.56M Buy
81,138
+40,915
+102% +$1.58M ﹤0.01% 2373
2024
Q2 		$1.58M Sell
40,223
-41,039
-51% -$1.69M ﹤0.01% 2305
2024
Q1 		$3.48M Buy
81,262
+80,430
+9,667% +$3.39M ﹤0.01% 2099
2023
Q4 		$33.9K Sell
832
-5,000
-86% -$287K ﹤0.01% 4822
2023
Q3 		$294K Buy
5,832
+4,700
+415% +$151K ﹤0.01% 3096
2023
Q2 		$47.1K Buy
+1,132
New +$31.7K ﹤0.01% 3865

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Barclays's GPCR Position: Q1 2026 in Review

Barclays increased its Structure Therapeutics (GPCR) stake by 145% in Q1 2026, buying an estimated $777K and bringing the position to 19,188 shares worth $925K. The position accounts for ﹤0.01% of the portfolio, ranked #2807.

Barclays first reported a position in GPCR in Q2 2023 and has held it in 12 quarters since. The position peaked at $3.56M in Q3 2024. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

  • Barclays held 19,188 shares of Structure Therapeutics worth $925K as of Q1 2026.
  • Barclays bought 11,355 Structure Therapeutics shares in Q1 2026, an estimated $777K.
  • Structure Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #2807 holding.
  • Barclays first reported a position in Structure Therapeutics in Q2 2023 and has held it in 12 quarters since.
  • Barclays's Structure Therapeutics position peaked at $3.56M in Q3 2024.
  • 196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.